Iron parenteral administration: an expert opinion on the assessment of fetal wellbeing

Abstract

Preview

Dear Sir,
Iron deficiency and iron deficiency anaemia represent global health issues1. They lead to an increased risk of adverse outcomes (Table I) and appropriate management is essential2. Among the new generation intravenous (IV) iron compounds, ferric carboxymaltose (FCM) is characterised by a free-dextrane structure which ensures less anaphylactic reactions; its nanomolecular stability minimises Fe3+ release3. As a result, FCM infusion is well-tolerated, facilitating rapid high-dose infusion. Data from two pharmacovigilance databases strengthen the evidence that iron isomaltoside 1000 is associated with a higher rate of severe hypersensitivity reactions than FCM. [ … ]